Somewhat Positive News Coverage Somewhat Unlikely to Affect Second Sight Medical Products (EYES) Stock Price
Media coverage about Second Sight Medical Products (NASDAQ:EYES) has trended somewhat positive on Tuesday, according to Accern. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Second Sight Medical Products earned a news sentiment score of 0.20 on Accern’s scale. Accern also assigned news articles about the medical device company an impact score of 46.14328422801 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have effected Accern’s scoring:
- Second Sight Medical (EYES) Says OHTAC Recommends Public Funding for its Argus II Retinal Prosthesis System – StreetInsider.com (streetinsider.com)
- Second Sight Medical (EYES) Announces FDA Expedited Access Pathway Designation for Orion Cortical Visual Prosthesis System (streetinsider.com)
- Second Sight Medical Products, Inc. :EYES-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017 (finance.yahoo.com)
- Ontario Health Technology Advisory Committee Recommends Public Funding for Second Sight’s Argus II Retinal Prosthesis System (finance.yahoo.com)
- ETFs with exposure to Second Sight Medical Products, Inc. : November 10, 2017 (finance.yahoo.com)
Second Sight Medical Products (EYES) traded up $0.02 on Tuesday, reaching $1.20. 121,600 shares of the company traded hands, compared to its average volume of 499,125. Second Sight Medical Products has a 52 week low of $0.90 and a 52 week high of $2.83.
Second Sight Medical Products (NASDAQ:EYES) last released its quarterly earnings data on Thursday, November 2nd. The medical device company reported ($0.12) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.14) by $0.02. The company had revenue of $1.61 million during the quarter, compared to the consensus estimate of $1.54 million. Second Sight Medical Products had a negative net margin of 565.12% and a negative return on equity of 171.77%. analysts predict that Second Sight Medical Products will post -0.55 earnings per share for the current year.
Several research analysts recently commented on EYES shares. HC Wainwright set a $5.00 price objective on shares of Second Sight Medical Products and gave the stock a “buy” rating in a report on Tuesday, August 8th. Zacks Investment Research downgraded shares of Second Sight Medical Products from a “hold” rating to a “sell” rating in a report on Thursday, August 10th.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Second Sight Medical Products (EYES) Stock Price” was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.thecerbatgem.com/2017/11/14/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-second-sight-medical-products-eyes-stock-price.html.
About Second Sight Medical Products
Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.
Receive News & Stock Ratings for Second Sight Medical Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products Inc. and related stocks with our FREE daily email newsletter.